WHO ICTRP trial
A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with…
NL-OMON52919 · Overview of Medical Research in the Netherlands (NL-OMON) · Not Recruiting
Key facts
| Trial ID | NL-OMON52919 |
|---|---|
| Public title | A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H) |
| Scientific title | A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H) - CA209-848 |
| Primary sponsor | Bristol-Myers Squibb |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 2 |
| Countries | The Netherlands |
| Conditions | Solid Tumors; Metastatic;10027476;Solid Tumors; Metastatic |
| Interventions | Participants will receive either nivolumab (240 mg) every 2 weeks combined with ipilimumab (1 mg/kg) every 6 weeks or Nivolumab alone (480mg) every 4 weeks. Both nivolumab and ipilimumab are provided by the sponsor. ;High Tumor Mutational… |
| Registration date | Jan 11, 2023 |
| Target size | 13 |
| Secondary IDs | 2016-002898-35;NL67171.031.18;U1111-1185-1326 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: